Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edwards, G.
Right arrow Articles by Jordan, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Edwards, G.
Right arrow Articles by Jordan, J.

Chest, Vol 70, 506-513, Copyright © 1976 by American College of Chest Physicians

ARTICLES

S-carboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction

GF Edwards, AE Steel, JK Scott and JW Jordan

The clinical results and changes in sputum found in both a short-term inpatient trial and a subsequent long-term outpatient investigation (three-month double-blind controlled study) of 82 patients with chronic bronchitis treated with a new mucolytic agent, S-carboxymethylcysteine (Mucodyne), are reported. Fluidification of sputum with reduction in certain measurements of the viscosity of morning sputum aliquots, associated with improvement in the ability to cough up bronchial secretions, significant increase in sputum volume output, and improvement in ventilation (as estimated by the forced expiratory volume in one second), were observed in both trials as dose-related responses, with an increase in the ease of expectoration and a reduction in cough frequency and dyspnea. Therapy with S- carboxymethylcysteine was well tolerated, and there were no serious adverse effects, either immediate or delayed. We suggest that the effect of the drug in fluidifying sputum may be due to a mucoregulatory mechanism which reverses the sputum macromolecular disturbances seen in chronic bronchitis.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
K. Takeda, N. Miyahara, T. Kodama, C. Taube, A. Balhorn, A. Dakhama, K. Kitamura, A. Hirano, M. Tanimoto, and E. W. Gelfand
S-carboxymethylcysteine normalises airway responsiveness in sensitised and challenged mice
Eur. Respir. J., October 1, 2005; 26(4): 577 - 585.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
P. J Poole and P. N Black

BMJ, May 26, 2001; 322(7297): 1271 - 1271.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by the American College of Chest Physicians.